18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off

[1]  Jochen Herrmann,et al.  Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1 , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  I. Apostolova,et al.  Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 , 2013, Clinical nuclear medicine.

[3]  G. Treglia,et al.  Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review , 2012, Radiology research and practice.

[4]  I. Steffen,et al.  Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Jedediah K. White,et al.  Multiagent PET for Risk Characterization in Sarcoma , 2011, The Journal of Nuclear Medicine.

[6]  N. Ishiguro,et al.  MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. , 2010, AJR. American journal of roentgenology.

[7]  J. Radford,et al.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  S. Dry,et al.  Quantitative F18‐fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign , 2010, Cancer.

[9]  M. Maeda,et al.  Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI , 2009, Journal of Cancer Research and Clinical Oncology.

[10]  R. Boellaard.  Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[11]  Hyun Woo Kwon,et al.  Prediction of Tumor Recurrence by 18F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma , 2009, Journal of Nuclear Medicine.

[12]  M. O'Doherty,et al.  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[14]  M. Schwaiger,et al.  Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine , 2008, Clinical Cancer Research.

[15]  M. O'Doherty,et al.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Kluwe,et al.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1 , 2006, Neuroradiology.

[17]  R. Buchert,et al.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Jason P Fine,et al.  Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J. Thie.  Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  P. Meltzer,et al.  Soft tissue sarcomas of adults: state of the translational science. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[22]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[23]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[24]  R. Ramanathan,et al.  Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  M Super,et al.  A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.

[26]  J. Charrow,et al.  Neurofibromatosis type 1 in childhood. , 1990, The Journal of pediatrics.

[27]  R. Beart,et al.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. , 1987 .

[28]  J. Duttenhaver.  Adult soft tissue sarcomas. , 1986, Journal of the Medical Association of Georgia.

[29]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.

[30]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[31]  D. Jukic.  Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2007 .

[32]  D Visvikis,et al.  Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. , 2001, European journal of nuclear medicine.

[33]  B. R. Korf,et al.  Plexiform neurofibromas. , 1999, American journal of medical genetics.

[34]  D. Gutmann,et al.  Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. , 1999, The American journal of surgical pathology.

[35]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. , 1988, Archives of neurology.